US House Drug Pricing Bill Amended To Target Launch Prices, Set For Swift Advance
House Speaker Pelosi’s amended HR 3 expands scope of targeted drugs, adds manufacturer transparency requirements ahead of dual markups and a hearing on 17 October.
You may also be interested in...
Now that US drug pricing reform seems inevitable, the Senate bill offers the most positive outcome for industry, Bernstein analyst Ronny Gal suggests.
The debate over price 'negotiation' in the US has taken a turn for the worse for innovator pharma companies. The Democratic party seems eager to plow forward no matter what the impact is on innovation – and some patient advocates are surprisingly eager to cheer them along.
A Republican congressman and witness discuss shortened IP protections while criticizing Nancy Pelosi's drug price negotiation plan.